Ask AI
See Activity Collection
ProCE Banner Activity

Treating TGCT Beyond the MRI: Restoring Function Through Individualized Care

Clinical Thought

This ClinicalThought commentary examines the biology and clinical management of tenosynovial giant cell tumor (TGCT), distinctions between localized and diffuse disease, and the roles of MRI and histologic confirmation in diagnosis and assessment. Learners will explore evidence and practice-relevant considerations for surgery, systemic CSF1R-targeted therapy such as pexidartinib and vimseltinib, treatment selection, monitoring, and longitudinal follow-up, while considering how symptoms, imaging findings, patient goals, and multidisciplinary care guide individualized treatment decisions.

Released: August 17, 2026

Begin Activity

Share

Faculty

William Tap

William Tap, MD

Chief, Sarcoma Medical Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Daiichi Sankyo, Inc.

Target Audience

This program is aligned with specific priorities outlined in the National Strategy for Quality Improvement in Health Care, in particular, making care safer by reducing harm caused in the delivery of care, promoting the most effective prevention and treatment practices for the leading causes of mortality, and promoting effective communication and coordination of care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the distinguishing clinical, radiologic, and pathologic features of localized and diffuse TGCT to support timely and accurate diagnosis

  • Evaluate current and emerging data on CSF1R-targeted therapies to inform treatment selection and sequencing for patients with TGCT

  • Coordinate multidisciplinary care approaches that involve key specialties to optimize TGCT treatment planning

  • Implement evidence-based strategies to monitor for and manage adverse events associated with CSF1R-targeted therapies, including hepatotoxicity and functional impact

  • Apply shared decision-making techniques to align treatment plans with individual patient values, preferences, and quality-of-life considerations in TGCT management

Financial Disclosures

Primary Author

William Tap, MD: other financial or material support: Cogent; consultant/advisor/speaker: Aadi, Abbisko, Boehringer Ingelheim, Curadev, Daiichi Sankyo, Deciphera, EMD Sernono, GSK, Ikena, Inhibrx, Ratio, Recordati, Synox.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.